Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine

JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5.  Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of

The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 Sep;20(5):1305-1315.doi: 10.1007/s13311-023-01404-1. Epub 2023 Jul 12. Diane Merino, Alexandre O Gérard, Elise K Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici Abstract Migraine constitutes the world’s second-leading cause of disability. Triptans, as

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

The Lancet Neurology 2022 Jul;21(7):597-607 doi: 10.1016/S1474-4422(22)00185-5. Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling Abstract Background: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and

Ketamine in chronic pain: A Delphi survey

European Journal of Pain 2022 Jan 29 doi: 10.1002/ejp.1914 Marion Voute, Thibault Riant, Jean-Marie Amodéo, Gilbert André, Mario Barmaki, Olivier Collard, Caroline Colomb, Christelle Créac’h, Rodrigue Deleens, Claire Delorme, Géraldine de Montgazon, Véronique Dixneuf, Lénaïg Dy , Jacques Gaillard , Christian Gov , Xavier Kieffer, Michel Lanteri-Minet, Jean-Marie Le Borgne, Franck Le Caër, Fadel Maamar, Caroline Maindet, Fabienne Marcaillou, Frédéric Plantevin, Yves-Marie Pluchon, Bruno

Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment

Revue Neurologique 2021 Sep;177(7):734-752. A Ducros, S de Gaalon, C Roos, A Donnet, P Giraud, E Guégan-Massardier, M Lantéri-Minet, C Lucas, J Mawet, X Moisset, D Valade, G Demarquay Abstract The French Headache Society proposes updated French guidelines for the

Phantom vision after eye removal: prevalence, features and related risk factors

The British Journal of Ophthalmology 2021 May 12; doi: 10.1136/bjophthalmol-2021-319091.  Arnaud Martel  , Stephanie Baillif  , Pierre Thomas  , Fabien Almairac  , Olivier Galatoire  , Mehrad Hamedani  , Denys Fontaine  , Michel Lanteri-Minet  Abstract Aim: Phantom eye syndrome is a poorly understood and underestimated complication of eye

Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study

Neurology 2021 Apr 28; doi: 10.1212/WNL.0000000000012029. Peter J Goadsby  , Uwe Reuter  , Michel Lanteri-Minet  , Gabriel Paiva da Silva Lima  , Peggy Hours-Zesiger  , Chrystel Fernandes  , Shihua Wen  , Nadia Tenenbaum  , Aditi Kataria  , Michel D Ferrari  , Jan Klatt  Abstract Objective: To report the efficacy and

QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France.

Curr Med Res Opin. 2019 Mar;35(3):417-426. doi: 10.1080/03007995.2018.1558850. Epub 2019 Jan 7. Lantéri-Minet M1,2, Perrot S3. Abstract OBJECTIVE: To describe the characteristics of patients treated with the capsaicin 8% patch, prescribing conditions, long-term effects of repeat treatment on pain intensity

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22. Reuter U1, Goadsby PJ2, Lanteri-Minet M3, Wen S4, Hours-Zesiger P5, Ferrari MD6, Klatt J5. Abstract BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate,